I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma

Abstract Background I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (~ 185 MBq, 10 mg). Seven of these patients undergoing sorafenib/immunot...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo, Ghassan K. Abou-Alfa
Médium: Artigo
Jazyk:Inglês
Vydáno: SpringerOpen 2018-03-01
Edice:EJNMMI Research
Témata:
Codrituzumab
I-124
Antibody
Glypican
Hepatocellular
On-line přístup:http://link.springer.com/article/10.1186/s13550-018-0374-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky